The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2026 | Insights into a Phase Ib/II trial of azacitidine, venetoclax, and ivosidenib in IDH1-mutated AML
Jennifer Marvin-Peek, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, provides insight into the findings from a Phase Ib/II trial (NCT03471260) investigating azacitidine, venetoclax, and ivosidenib in patients with IDH1-mutated acute myeloid leukemia (AML). Dr Marvin-Peek notes encouraging response rates, survival outcomes, and high rates of measurable residual disease (MRD) negativity observed with this triplet regimen. She also highlights the favorable safety of the combination, which appears comparable to doublet regimens. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
